Related references
Note: Only part of the references are listed.Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma
Elizabeth R. Gerstner et al.
CLINICAL CANCER RESEARCH (2020)
Prognostic value of radiomic analysis of iodine overlay maps from dual-energy computed tomography in patients with resectable lung cancer
Jooae Choe et al.
EUROPEAN RADIOLOGY (2019)
Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer
David F. Heigener et al.
CLINICAL CANCER RESEARCH (2019)
Evaluation of response to conventional chemotherapy and radiotherapy by perfusion computed tomography in non-small cell lung cancer (NSCLC)
Carmen Trinidad Lopez et al.
EUROPEAN RADIOLOGY EXPERIMENTAL (2019)
Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups
Hidetake Yabuuchi et al.
RADIOLOGY (2018)
SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer
G. Fernandez-Perez et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2018)
Stability of radiomic features in CT perfusion maps
M. Bogowicz et al.
PHYSICS IN MEDICINE AND BIOLOGY (2016)
Dynamic Volume Perfusion Computed Tomography Parameters versus RECIST for the Prediction of Outcome in Lung Cancer Patients Treated with Conventional Chemotherapy
Sonja Sudarski et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Whole-tumour CT-perfusion of unresectable lung cancer for the monitoring of anti-angiogenetic chemotherapy effects
F. Fraioli et al.
BRITISH JOURNAL OF RADIOLOGY (2013)
Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy
Nunzia Tacelli et al.
EUROPEAN RADIOLOGY (2013)
Assessment of Tumor Vascularity in Lung Cancer Using Volume Perfusion CT (VPCT) With Histopathologic Comparison: A Further Step Toward an Individualized Tumor Characterization
Daniel Spira et al.
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY (2013)
Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
Astrid A. M. Van der Veldt et al.
CANCER CELL (2012)
Predictive Value of Intratumoral Microvascular Density in Patients with Advanced Non-small Cell Lung Cancer Receiving Chemotherapy Plus Bevacizumab
Yuan-Yuan Zhao et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Whole-Tumor Perfusion CT in Patients with Advanced Lung Adenocarcinoma Treated with Conventional and Antiangiogenetic Chemotherapy: Initial Experience
Francesco Fraioli et al.
RADIOLOGY (2011)
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Joline S. W. Lind et al.
EUROPEAN RADIOLOGY (2010)
Microvascular Endothelial Cell Responses in vitro and in vivo: Modulation by Zoledronic Acid and Paclitaxel?
Maria Michailidou et al.
JOURNAL OF VASCULAR RESEARCH (2010)
Assessment of Non-Small Cell Lung Cancer Perfusion: Pathologic-CT Correlation in 15 Patients
Nunzia Tacelli et al.
RADIOLOGY (2010)
Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Perfusion CT Evaluation of Chemotherapy and Radiation Therapy
Jianwei Wang et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Paclitaxel induces vascular endothelial growth factor expression through reactive oxygen species production
Hyun Sun Kim et al.
PHARMACOLOGY (2008)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells
E Pasquier et al.
CANCER RESEARCH (2005)
Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer
AB Sandler et al.
CLINICAL CANCER RESEARCH (2004)
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
JE Ohm et al.
BLOOD (2003)